Sapient Capital LLC Sells 326,646 Shares of Intensity Therapeutics Inc. $INTS

Sapient Capital LLC decreased its stake in shares of Intensity Therapeutics Inc. (NASDAQ:INTS) by 33.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 650,151 shares of the company’s stock after selling 326,646 shares during the quarter. Sapient Capital LLC owned about 1.08% of Intensity Therapeutics worth $244,000 at the end of the most recent quarter.

Separately, Mesirow Financial Investment Management Inc. lifted its position in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares during the last quarter. 3.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Intensity Therapeutics Stock Performance

NASDAQ:INTS opened at $4.59 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.86 and a current ratio of 4.86. The company has a fifty day moving average of $5.67 and a two-hundred day moving average of $8.63. The stock has a market capitalization of $12.39 million, a PE ratio of -0.80 and a beta of 2.94. Intensity Therapeutics Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. As a group, research analysts forecast that Intensity Therapeutics Inc. will post -2.7 earnings per share for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.